Earnings ·
RxSight reported second quarter 2026 total revenue of $33.7 million, including $6.5 million from a strategic…
RXSTRxSight, Inc.
RxSight reported second quarter 2026 total revenue of $33.7 million, including $6.5 million from a strategic collaboration with Alcon, while product sales declined 19% year-over-year to $27.2 million due to competitive pressure. The company appointed Aziz Mottiwala as President and CEO and withdrew its 2026 financial guidance to allow for a comprehensive business review ahead of resuming formal guidance in early 2027. Net loss was $12.1 million, or $0.29 per share, compared to a net loss of $11.8 million in the prior year period. The company holds approximately $209 million in cash and short-term investments as of June 30, 2026. RxSight operates in the ophthalmic medical device industry, specializing in light-adjustable intraocular lenses for cataract surgery.